NEUROPATHIC PAIN MARKET ANALYSIS

Neuropathic Pain Market, by Drug Class (Tricyclic Anti-Depressant, Anticonvulsant, Local Anaesthesia, Opioids, Steroids, Others), By Indication (Diabetic neuropathy, Chemotherapy-induced Peripheral neuropathy and Others), By Distribution Channel (Retail Pharmacies, Drug Store and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2023
Code : CMI3656
Pages :168
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Neuropathic Pain Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global neuropathy pain market over the forecast period due to increasing research and developments activities for neuropathy drugs increase global neuropathic pain market. For instance, in September 2021, Biogen, a U.S.-based biotechnology company, announced positive results of Vixotrigine from phase 2. Vixotrigine a non-opioid oral pain drug evaluate for the treatment of chronic painful neuropathy.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa